Roche has reported overall survival outcomes from a Phase III trial of Perjeta with Herceptin and chemotherapy in early-stage ...

Connect Biopharma has begun a Phase II trial to assess rademikibart for treating acute exacerbations of asthma and type II ...

GlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033, with Novo Nordisk and Eli Lilly to dominate ...

The human immunodeficiency virus (HIV) market across the seven major markets (7MM), comprising the US, France, Germany, Italy ...

The Trump administration has introduced legislation outlining plans for deep cuts to Medicaid, possibly impacting millions of ...

The Danish multinational said that Sogroya improved the yearly growth rate in pre-pubertal children born small for ...

LEO Pharma has reported topline outcomes from the Phase IIb trial of temtokibart, a potential new treatment for atopic ...

Johnson & Johnson (J&J) has reported new data from the Phase III ICONIC-TOTAL trial, assessing icotrokinra in treating plaque ...

NMIBC is becoming more prominent as its incidence is correlated with older age groups, with the median age being 70 when ...

AstraZeneca's Imfinzi, when combined with standard-of-care BCG induction and maintenance therapy, showed DFS improvement.

Vir Biotechnology announced the data during the EASL conference on Friday. Image credit: Shutterstock / T Schneider. Vir ...

A panel at OCT Europe touched upon where the European clinical trial industry is headed and the impact of technology and ...